You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 847 Optimal dose selection of ADG126 (a masked anti-CTLA-4 SAFEbody®) with significantly widened therapeutic index compared to ipilimumab in combination with anti-PD-1 antibodies informed by QSP modeling

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
847 Optimal dose selection of ADG126 (a masked anti-CTLA-4 SAFEbody®) with significantly widened therapeutic index compared to ipilimumab in combination with anti-PD-1 antibodies informed by QSP modeling

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023142019
Dec 20235209
Jan 20243904
Feb 20245407
Mar 20244606
Apr 202448011
May 20242802
Jun 20247804
Jul 202466013
Aug 20244008
Sep 20243404
Oct 202440011
Nov 202460010
Dec 20243209
Jan 20256205
Feb 20251104
Mar 20250020
Apr 2025007
May 20250012
Jun 2025009
Total8320174